Muscat: VLCC, a widely recognised brand for its comprehensive portfolio of wellness and beauty services and products, announced the launch of a new non-invasive body contouring and slimming treatment in Oman, which uses US-FDA approved laser technology to remove excess fat from the body without any surgical procedure.

The VLCC Lipo-1060 treatment uses the very latest laser appliance of a very specific wavelength, enabling non-invasive body contouring and slimming without pain and ensuring that only fat cells are eliminated while the skin is protected. The technology used in the treatment has been clinically proven for consistently reducing the fat contour in the abdomen and other areas of the body, with an excellent safety profile in all skin types.

The effect of the treatment is enhanced by vacuum technology and can be delivered in only 25 minutes per session, with no recovery time required. Safe and hygienic, the process is specifically designed to protect the skin from heat of laser and requires no human touch.

Speaking on the occasion of the launch of the new service, Mrs. Vandana Luthra, Founder, VLCC said, “In its over 30-year legacy of technical expertise, performance and operational excellence in the wellness & beauty services and products domain, VLCC has always led the way, in the 12 countries across Asia and East Africa where it operates, when it comes to introducing the very latest in technological advances. The VLCC Lipo-1060 treatment is another example of this.”

Mrs Vandana Luthra, Founder & Co-Chairperson, VLCC Group

The treatment is supported by expert advice on nutrition and daily diet planning as well as physical activity regimen, which is customised for each individual depending upon their respective body composition, dietary habits and medical condition, if any. The whole program is conducted by specialists, including nutritionists, physiotherapists and laser experts, under the supervision of a medical doctor.

VLCC is the first wellness & beauty company to introduce this high-technology based treatment in Oman. 

VLCC is said to go public in India later this year. As per Mrs. Vandana’s statement in the press conference the IPO size is said to be INR 300 crores and the secondary offer is a sale of shares by existing shareholders comprising 23.69% of the pre-Issue paid-up capital.